JHS Svendgaard Laboratories Limited (IN:JHS)
:JHS
Want to see IN:JHS full AI Analyst Report?
Top Page
JHS Svendgaard Laboratories Limited
(JHS)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹9.50
▲(1.71% Upside)
Action:ReiteratedDate:04/17/26
The score is held back primarily by weak financial performance—multi-year revenue decline, sustained losses, and worsening free cash flow—despite a strong low-leverage balance sheet. Technicals are modestly supportive in the short term but weaker versus longer-term averages, and valuation (P/E ~27) offers limited margin of safety without a dividend.
Positive Factors
Low leverage / strong balance sheet
Very high equity ratio and negligible debt give durable financial flexibility. This lowers refinancing and interest-rate risk, supports capital spending or working-capital needs, and provides a stable runway for operational restructuring or capacity investments over the next several quarters.
Negative Factors
Multi-year revenue decline
Persistent top-line contraction reduces operating leverage and leaves production capacity underutilized. For a volume-driven contract manufacturer, declining revenue impairs fixed-cost absorption, weakens bargaining power with suppliers, and makes margin recovery and scale economics harder to achieve.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very high equity ratio and negligible debt give durable financial flexibility. This lowers refinancing and interest-rate risk, supports capital spending or working-capital needs, and provides a stable runway for operational restructuring or capacity investments over the next several quarters.
Read all positive factors
JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹770.44M
Dividend YieldN/A
Average Volume (3M)16.78K
Price to Earnings (P/E)27.3
Beta (1Y)1.10
Revenue Growth6.42%
EPS Growth61.96%
CountryIN
Employees250
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)0.09
Shares Outstanding85,603,966
10 Day Avg. Volume16,348
30 Day Avg. Volume16,781
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.06
P/FCF Ratio-6.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
JHS Svendgaard Laboratories Limited Business Overview & Revenue Model
Company Description
JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures and sells a range of oral and dental products for adults and kids in India. The company offers oral care products, such as toothbrushes, toothpastes, mouthwash produ...
How the Company Makes Money
JHS primarily makes money by manufacturing oral care/personal care products and selling them to brand owners (including FMCG companies) under contract manufacturing and private-label agreements. Revenue is typically generated on a per-unit or per-...
JHS Svendgaard Laboratories Limited Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
55
Neutral
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 935.64M | 919.97M | 698.06M | 840.82M | 854.91M | 1.00B |
| Gross Profit | 329.55M | 309.55M | 203.55M | 165.45M | 201.68M | 264.03M |
| EBITDA | -15.86M | -39.92M | 33.78M | -163.82M | 85.45M | 94.57M |
| Net Income | -79.38M | -197.44M | -40.58M | -175.17M | -40.52M | 11.98M |
Balance Sheet | ||||||
| Total Assets | 2.07B | 2.01B | 1.97B | 2.28B | 2.22B | 2.28B |
| Cash, Cash Equivalents and Short-Term Investments | 200.11M | 200.16M | 94.56M | 386.51M | 80.19M | 230.38M |
| Total Debt | 105.87M | 64.58M | 51.29M | 155.09M | 61.82M | 70.11M |
| Total Liabilities | 332.52M | 284.41M | 271.70M | 543.87M | 269.46M | 299.97M |
| Stockholders Equity | 1.74B | 1.73B | 1.70B | 1.74B | 1.86B | 1.89B |
Cash Flow | ||||||
| Free Cash Flow | -29.85M | -157.11M | -401.17M | 89.43M | -158.75M | 36.96M |
| Operating Cash Flow | -29.85M | -51.78M | -85.84M | 232.86M | -91.36M | 120.29M |
| Investing Cash Flow | 92.77M | -220.18M | -217.34M | 96.77M | -46.97M | -22.25M |
| Financing Cash Flow | 38.02M | 232.97M | 21.74M | -9.00M | -16.72M | 103.09M |
JHS Svendgaard Laboratories Limited Technical Analysis
Positive
9.34
Price Trends
9.14
Positive
9.73
Negative
10.89
Negative
Market Momentum
0.10
Negative
60.95
Neutral
65.47
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Positive. The current price of 9.34 is above the 20-day moving average (MA) of 8.03, above the 50-day MA of 9.14, and below the 200-day MA of 10.89, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 60.95 is Neutral, neither overbought nor oversold. The STOCH value of 65.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JHS.
JHS Svendgaard Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹590.92B | 43.58 | ― | 2.42% | -2.73% | -9.21% | |
66 Neutral | ₹801.97B | 39.88 | ― | 1.62% | 3.48% | 2.69% | |
64 Neutral | ₹202.06B | 18.06 | ― | 1.91% | 2.14% | 0.13% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | ₹1.11T | 62.79 | ― | 1.67% | 7.29% | ― | |
54 Neutral | ₹113.49B | 46.47 | ― | ― | 13.17% | 98.58% | |
49 Neutral | ₹770.44M | 27.28 | ― | ― | 6.42% | 61.96% |
* Consumer Defensive Sector Average
IN:JHS
JHS Svendgaard Laboratories Limited
9.22
-4.38
-32.21%
IN:COLPAL
Colgate-Palmolive (India) Limited
2,139.65
-449.21
-17.35%
IN:DABUR
Dabur India Limited
452.35
-24.03
-5.04%
IN:EMAMILTD
Emami Limited
461.20
-159.67
-25.72%
IN:GODREJCP
Godrej Consumer Products Limited
1,089.40
-151.95
-12.24%
IN:HONASA
Honasa Consumer Limited
347.55
98.55
39.58%
JHS Svendgaard Laboratories Limited Corporate Events
JHS Svendgaard Grants 250,000 Stock Options Under 2025 ESOP
Feb 10, 2026
JHS Svendgaard Laboratories Limited’s Nomination and Remuneration Committee has approved the grant of 250,000 employee stock options under its 2025 Employee Stock Option Scheme, each option convertible into one equity share of face value Rs....
JHS Svendgaard Completes Rs 3.75 Crore Preferential Allotment to Coeus Global Opportunities Fund
Feb 1, 2026
JHS Svendgaard Laboratories Limited has approved the conversion of 18,01,801 fully convertible warrants into an equal number of equity shares of face value Rs 10 each at an issue price of Rs 27.75 per share, following receipt of the remaining 75% ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.